Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets
To exploit highly conserved and difficult drug targets, including multipass membrane proteins, monoclonal antibody discovery efforts increasingly rely on the advantages offered by divergent species such as rabbits, camelids, and chickens. Here, we provide an overview of antibody discovery technologi...
Saved in:
| Main Authors: | Soma S.R. Banik, Natasha Kushnir, Benjamin J. Doranz, Ross Chambers |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2273018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
VERITAS: Harnessing the power of nomenclature in biologic discovery
by: Riti Biswas, et al.
Published: (2023-12-01) -
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
by: Vaishali Verma, et al.
Published: (2025-12-01) -
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
by: Ruoxuan Sun, et al.
Published: (2024-12-01) -
Chicken NLRP3 monoclonal antibody development and its antigenic epitope identification
by: Mengmeng Xu, et al.
Published: (2025-11-01) -
The Application of Machine Learning on Antibody Discovery and Optimization
by: Jiayao Zheng, et al.
Published: (2024-12-01)